ITI Pharma and Healthcare Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
ITI Pharma and Healthcare Fund is a Thematic fund and Nippon India Pharma Fund is a Sectoral fund. In the 3 years to 30-10-2026, ITI Pharma and Healthcare Fund (Direct) returned 20.3% a year and Nippon India Pharma Fund (Direct) returned 18.6% a year. ITI Pharma and Healthcare Fund charges 0.89% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 57.6%: they hold 20 of the same securities.
ITI Pharma and Healthcare Fund
Thematic
- 3 year return
- 20.3%
- Expense ratio
- 0.89%
- NAV
- ₹19.46
Nippon India Pharma Fund
Sectoral
- 3 year return
- 18.6%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Which is better, ITI Pharma and Healthcare or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- ITI Pharma and Healthcare returned more over 3 years: 20.3% a year against 18.6%.
- ITI Pharma and Healthcare returned more over 1 year: 9.4% against 9.1%.
- ITI Pharma and Healthcare costs less: 0.89% a year against 0.99% (Direct plans).
- Nippon India Pharma swung less over 3 years: a standard deviation of 13.0% a year against 14.2%.
- ITI Pharma and Healthcare fell less in its worst fall since 11-11-2021: −17.7% against −18.7%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹266 Cr.
- Their portfolios overlap 57.6%: 20 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | ITI Pharma and Healthcare Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | ITI Mutual Fund | Nippon India Mutual Fund |
| Category | Thematic | Sectoral |
| AUM | ₹266 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹19.46 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 0.89% | 0.99% |
| Expense ratio (Regular) | 2.59% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | NIFTY Healthcare TRI | BSE Healthcare TRI |
| Launch date | 08-11-2021 | 05-06-2004 |
| Minimum investment | ₹5,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Animesh Singh, Nilay Dalal | Sailesh Raj Bhan |
| Exit load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 1 month. |
ITI Pharma and Healthcare vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 0.00% | −1.04% | +11.74% | +9.43% | +20.30% | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 235 Thematic funds and the 20 Sectoral funds, same plan type.
ITI Pharma and Healthcare vs Nippon India Pharma: Year-wise Returns
| Year | ITI Pharma and HealthcareITI Pharma and Healthcare | Nippon India PharmaNippon India Pharma |
|---|---|---|
| 2026to date | +14.07% | +9.76% |
| 2025 | −8.24% | −2.46% |
| 2024 | +43.95% | +35.26% |
| 2023 | +34.39% | +40.36% |
| 2022 | −6.68% | −9.06% |
| 2021 | -- | +25.12% |
ITI Pharma and Healthcare vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against Nifty Healthcare Index TRI, the benchmark of ITI Pharma and Healthcare Fund
Rolling returns
Every 3-year holding period, 485 of them, one for each trading day from 11-11-2024 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Healthcare Index TRI
to
Jan 2025May 2022
to
May 2025Sept 2022
to
Sept 2025Jan 2023
to
Jan 2026May 2023
to
May 2026Sept 2023
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare | 0.0 | 0.0 | 0.0 | 0.0 | 14.0 | 79.8 | 6.2 | 21.7% | 21.4% | 17.3% | 26.9% | 49% |
| Nippon India Pharma | 0.0 | 0.0 | 0.0 | 0.0 | 25.4 | 61.6 | 13.0 | 22.0% | 22.3% | 15.9% | 27.2% | 59% |
| Nifty Healthcare Index TRI | 0.0 | 0.0 | 0.0 | 0.0 | 24.7 | 67.8 | 7.4 | 21.8% | 22.2% | 15.6% | 27.3% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty Healthcare Index TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 11-11-2021. Past returns do not promise future returns.
ITI Pharma and Healthcare vs Nippon India Pharma: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 11-11-2021 to 30-10-2026: 60 instalments, ₹6,00,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct) | ₹6,00,000 | ₹9,07,480 | ₹3,07,480 | 16.6% |
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹6,00,000 | ₹8,95,536 | ₹2,95,536 | 16.1% |
ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct)
Nippon India PharmaNippon India Pharma Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
ITI Pharma and Healthcare vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.43% | +9.05% |
| Standard deviation | 13.63% | 12.27% |
| Sharpe ratio | 0.31 | 0.31 |
| Sortino ratio | 0.44 | 0.45 |
| Maximum drawdown | −11.7% (29-01-2026) | −9.6% (23-10-2026) |
| Beta | 0.91 | 0.87 |
| Alpha | −1.48% | −2.40% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +20.30% | +18.56% |
| Standard deviation | 14.17% | 12.96% |
| Sharpe ratio | 1.01 | 0.97 |
| Sortino ratio | 1.41 | 1.39 |
| Maximum drawdown | −17.1% (03-03-2025) | −14.7% (28-02-2025) |
| Beta | 0.90 | 0.88 |
| Alpha | +0.31% | −2.50% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | ITI Pharma and Healthcare Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +14.34% | +17.18% |
| Standard deviation | 13.44% | 15.19% |
| Sharpe ratio | 0.63 | 0.73 |
| Sortino ratio | 0.89 | 1.06 |
| Maximum drawdown | −17.7% (17-06-2022) | −24.0% (29-05-2017) |
| Beta | 0.84 | 0.85 |
| Alpha | +1.08% | +3.72% |
From daily NAVs, 11-11-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Healthcare Index TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | −17.7% | 13-01-2022 | 17-06-2022 | 16-06-2023 | 12 months | −4.2% |
| Nippon India Pharma Fund (Direct) | −18.7% | 31-12-2021 | 17-06-2022 | 21-06-2023 | 12 months | −4.3% |
| Nifty Healthcare Index TRI | −18.3% | 31-12-2021 | 17-06-2022 | 30-06-2023 | 12 months | −2.9% |
From daily values since 11-11-2021, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Healthcare Index TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
ITI Pharma and Healthcare Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Healthcare Index TRI
Against Nifty Healthcare Index TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 94% | 87% | 5.10% |
| Nippon India Pharma Fund (Direct) | 88% | 80% | 4.27% |
From month-end values since 11-11-2021. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
ITI Pharma and Healthcare vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: ITI Pharma and Healthcare Fund, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 57.6%
- Held by both
- 20
- Only in ITI Pharma and Healthcare
- 17
- Only in Nippon India Pharma
- 16
| Security | % of ITI Pharma and Healthcare | % of Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.96% | 11.71% |
| Divi's Laboratories Limited | 9.51% | 7.10% |
| Apollo Hospitals Enterprise Limited | 5.45% | 4.89% |
| Dr. Reddy's Laboratories Limited | 4.78% | 5.45% |
| Cipla Limited | 4.19% | 6.01% |
| Mankind Pharma Limited | 3.78% | 4.38% |
| Max Healthcare Institute Limited | 4.49% | 2.70% |
| Abbott India Limited | 2.14% | 2.32% |
| Lupin Limited | 2.04% | 6.17% |
| IPCA Laboratories Limited | 1.94% | 2.87% |
| Sai Life Sciences Limited | 1.87% | 3.92% |
| Alkem Laboratories Limited | 3.09% | 1.82% |
| Aurobindo Pharma Limited | 4.01% | 1.65% |
| Piramal Pharma Limited | 1.27% | 2.24% |
| Anthem Biosciences Limited | 1.25% | 1.19% |
| Fortis Healthcare Limited | 2.77% | 1.13% |
| Gland Pharma Limited | 1.03% | 2.53% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.96% | 3.11% |
| Biocon Limited | 0.81% | 1.01% |
| Syngene International Limited | 0.57% | 1.40% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 57.6% means 57.6% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in ITI Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Torrent Pharmaceuticals Limited | 4.78% |
| Laurus Labs Limited | 4.02% |
| Cohance Lifesciences Limited | 3.14% |
| Neuland Laboratories Limited | 3.07% |
| Global Health Limited | 2.85% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Ajanta Pharma Limited | 3.61% |
| Vijaya Diagnostic Centre Limited | 2.62% |
| MedPlus Health Services Limited | 2.53% |
| Thyrocare Technologies Limited | 2.24% |
| Dr. Lal Path Labs Limited | 2.17% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | ITI Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Equity | 99.3% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.7% | 2.7% |
Market cap of stocks
| Market cap | ITI Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Large Cap | 35.9% | 29.7% |
| Mid Cap | 40.5% | 39.0% |
| Small Cap | 23.0% | 28.0% |
| Not on AMFI's list | 0.0% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | ITI Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.8% | 74.0% |
| Healthcare Services | 20.9% | 20.3% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 1.5% | 0.5% |
| Consumer Durables | 1.2% | 0.0% |
| Chemicals & Petrochemicals | 0.9% | 0.0% |
The six largest sectors of each fund's stocks, % of the fund.
ITI Pharma and Healthcare vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | ITI Pharma and Healthcare Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.89% | 0.99% |
| Base expense ratio (Direct) | 0.58% | 0.79% |
| Total expense ratio (Regular) | 2.59% | 1.85% |
| Base expense ratio (Regular) | 2.10% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare ITI Pharma and Healthcare with
ITI Pharma and Healthcare Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between ITI Pharma and Healthcare Fund and Nippon India Pharma Fund?
ITI Pharma and Healthcare Fund is a Thematic fund, Nippon India Pharma Fund is a Sectoral fund, run by ITI Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 57.6%. ITI Pharma and Healthcare Fund charges 0.89% a year and Nippon India Pharma Fund 0.99%.
Which has given higher returns, ITI Pharma and Healthcare Fund or Nippon India Pharma Fund?
Over 1 year: ITI Pharma and Healthcare Fund +9.43%, Nippon India Pharma Fund +9.05%. Over 3 years: ITI Pharma and Healthcare Fund +20.30% a year, Nippon India Pharma Fund +18.56% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, ITI Pharma and Healthcare Fund or Nippon India Pharma Fund?
ITI Pharma and Healthcare Fund charges less: 0.89% a year against 0.99%. These are the Direct plans' total expense ratios reported to AMFI.
How much do ITI Pharma and Healthcare Fund and Nippon India Pharma Fund overlap?
57.6%. They hold 20 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, ITI Pharma and Healthcare Fund or Nippon India Pharma Fund?
On SEBI's riskometer, ITI Pharma and Healthcare Fund is rated Very High and Nippon India Pharma Fund Very High. Over 3 years, the standard deviation of daily returns was 14.17% and 12.96% a year.
Which is better for SIP, ITI Pharma and Healthcare Fund or Nippon India Pharma Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹4,46,688 in ITI Pharma and Healthcare Fund (XIRR 12.3% a year) and ₹4,36,963 in Nippon India Pharma Fund (XIRR 10.8% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both ITI Pharma and Healthcare Fund and Nippon India Pharma Fund?
Yes. 57.6% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages ITI Pharma and Healthcare Fund and Nippon India Pharma Fund?
ITI Pharma and Healthcare Fund: Animesh Singh, Nilay Dalal. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.